Report Adverse Event or Product Quality Complaint    US Site     Global Site

AZmedical Information Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ACAAI 2026

American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - 2026

November 12 - 16, 2026

  1. All
  2. FASENRA (benralizumab)
  3. AIRSUPRA (albuterol/budesonide)
  4. TEZSPIRE (tezepelumab)
  5. Respiratory Unbranded
  6. BREZTRI/TRIXEO

HTML

Retrospective analysis of lung function improvement with benralizumab in patients with uncontrolled moderate-to-severe asthma

HTML

Budesonide/glycopyrronium/formoterol fumarate dihydrate treatment effects by T2 biomarkers: KALOS and LOGOS studies post hoc analyses

PDF

Tezepelumab reduced all-cause systemic corticosteroid receipt in adults with inadequately controlled CRSwNP in WAYPOINT

PDF

Tezepelumab improved outcomes across baseline blood eosinophil counts in adults with severe CRSwNP in WAYPOINT

PDF

Tezepelumab improves upper and lower airway outcomes in patients with severe asthma and comorbid CRSwNP

PDF

Tezepelumab associated with improved airway epithelial integrity in patients with allergic or eosinophilic moderate-to-severe asthma

PDF

Treatment patterns of Medicare and Medicaid patients with uncontrolled asthma in Puerto Rico

PDF

Large and small airways response to albuterol-budesonide versus albuterol following acute mannitol-induced obstruction

PDF

GRANITE: Real-world corticosteroid use in patients with asthma using albuterol-budesonide versus albuterol

HTML

Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS): Improvements in rhinitis symptoms and quality of life

HTML

Retrospective analysis of lung function improvement with benralizumab in patients with uncontrolled moderate-to-severe asthma

HTML

Budesonide/glycopyrronium/formoterol fumarate dihydrate treatment effects by T2 biomarkers: KALOS and LOGOS studies post hoc analyses

PDF

Large and small airways response to albuterol-budesonide versus albuterol following acute mannitol-induced obstruction

PDF

GRANITE: Real-world corticosteroid use in patients with asthma using albuterol-budesonide versus albuterol

PDF

Tezepelumab reduced all-cause systemic corticosteroid receipt in adults with inadequately controlled CRSwNP in WAYPOINT

PDF

Tezepelumab improved outcomes across baseline blood eosinophil counts in adults with severe CRSwNP in WAYPOINT

PDF

Tezepelumab improves upper and lower airway outcomes in patients with severe asthma and comorbid CRSwNP

PDF

Tezepelumab associated with improved airway epithelial integrity in patients with allergic or eosinophilic moderate-to-severe asthma

HTML

Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS): Improvements in rhinitis symptoms and quality of life

PDF

Treatment patterns of Medicare and Medicaid patients with uncontrolled asthma in Puerto Rico

HTML

Budesonide/glycopyrronium/formoterol fumarate dihydrate treatment effects by T2 biomarkers: KALOS and LOGOS studies post hoc analyses

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States